Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals Inc. | Plozasiran (ARO-APOC3) - (CAPITAN) | Mixed hyperlipidemia | Phase 3 | Trial Planned | Subcutaneous | Cardiology |
| Arrowhead Pharmaceuticals Inc. | Fazirsiran (ARO-AAT) - (SEQUOIA) | Alpha-1 Liver Disease | Phase 2/3 | Ongoing | Subcutaneous | Genetic Disorder |
| Artelo Biosciences Inc. | ART27.13 - (CAReS) | Cancer-Related Anorexia and Weight Loss | Phase 2 | Data Released | oral | Oncology |
| Arvinas Inc. | Vepdegestrant (ARV-471) - (VERITAC-2) | Breast cancer | PDUFA | Ongoing | Oral | Oncology |
| Arvinas Inc. | Samuraciclib (CT7001) and vepdegestrant (ARV-471) | ER+, HER2- metastatic breast cancer | PDUFA | Ongoing | Oral | Oncology |
| Arvinas Inc. | ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N) | ER+ positive / HER2- negative breast cancer | Phase 2 | Data Released | Oral | Oncology |
| Arvinas Inc. | Atirmociclib (PF-07220060) with endocrine therapy (ET) - (TACTIVE-K) | HR+/HER metastatic breast cancer | Phase 3 | Ongoing | Oral | Oncology |
| Ascendis Pharma A/S | TransCon hGH/TransCon CNP combination - (COACH) | Achondroplasia | Phase 2 | Data Released | Subcutaneous | Genetic Disorder |
